Medpace (NASDAQ:MEDP) CEO August Troendle Sells 668 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 668 shares of Medpace stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Medpace Price Performance

Shares of MEDP stock traded down $2.78 during trading hours on Friday, hitting $542.00. The stock had a trading volume of 16,384 shares, compared to its average volume of 408,522. The stock has a market capitalization of $15.27 billion, a price-to-earnings ratio of 37.90, a PEG ratio of 2.17 and a beta of 1.43. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $626.26. The stock’s 50-day moving average price is $566.87 and its two-hundred day moving average price is $451.00.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter last year, the business posted $3.01 EPS. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MEDP. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Mizuho boosted their target price on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. BMO Capital Markets began coverage on shares of Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Robert W. Baird set a $613.00 price target on Medpace in a research report on Friday, October 24th. Finally, Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $487.18.

Hedge Funds Weigh In On Medpace

A number of large investors have recently bought and sold shares of MEDP. Quent Capital LLC purchased a new stake in Medpace in the third quarter worth $25,000. Optiver Holding B.V. bought a new position in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group increased its stake in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after buying an additional 71 shares during the period. Finally, Quarry LP bought a new stake in Medpace during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.